ELMS STEVE
Transaction: 11/17/2025
BUY
Change
+84,411
Price
$0.95
Filing
11/19/2025
Type
BUY
Marker Therapeutics, Inc.
MRKR • Biotechnology
$1.18
▼ -0.06 (-4.84%)
Current price
EarningsLatest report: Jun 30, 2026
BALANCED PROFILENeutralConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$22.79M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Positive revenue growth · 65.4%Manageable debt level · 0Healthy liquidity · 8.39Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 16, 2026, 12:16 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$1.18
Change-4.84%
Shares Out19.31M
Market Cap$22.79M
Enterprise Value$11.46M
52W Range0.81 - 2.46
Beta1.51
P/E-2.62
P/S18.49
P/B1.87
P/FCF-2.34
EV/Sales9.30
Price$1.18
Change-4.84%
Shares Out19.31M
Market Cap$22.79M
Enterprise Value$11.46M
52W Range0.81 - 2.46
Beta1.51
P/E-2.62
P/S18.49
P/B1.87
P/FCF-2.34
EV/Sales9.30
EV/EBITDA-1.08
EV/FCF-1.17
Earnings Yield-38.20%
FCF Yield-42.81%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio8.39
Quick Ratio8.39
Volume45.55K
Avg Volume61.53K
EPS Surprise0.02
Investment DNA
How strong this company looks for long-term investors
55
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
92/100
Why this score▼
Positive revenue growth · 65.4%Manageable debt level · 0Healthy liquidity · 8.39Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 5 analyst votes · 2026-09-05
80/100
Bullish
Bullish
3
Hold
2
Bearish
0
Insider Transactions
Recent executive and insider activity
Eansor Norman David
Transaction: 11/17/2025
BUY
Change
+84,411
Price
$0.95
Filing
11/19/2025
Type
BUY
Knobil Katharine
Transaction: 11/17/2025
BUY
Change
+84,411
Price
$0.95
Filing
11/19/2025
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| ELMS STEVE | BUY | +84,411 | $0.95 | 11/17/2025 | 11/19/2025 |
| Eansor Norman David | BUY | +84,411 | $0.95 | 11/17/2025 | 11/19/2025 |
| Knobil Katharine | BUY | +84,411 | $0.95 | 11/17/2025 | 11/19/2025 |
| Corzo Kathryn Penkus | OTHER | 0 | Not reported | 10/31/2025 | 11/04/2025 |
| Vera Juan | BUY | +250,000 | $0.99 | 10/31/2025 | 11/04/2025 |
| Corzo Kathryn Penkus | BUY | +147,611 | $0.99 | 10/31/2025 | 11/04/2025 |
| Vera Juan | BUY | +50,000 | $1.59 | 02/12/2025 | 02/14/2025 |
| Eansor Norman David | BUY | +30,000 | $1.59 | 02/12/2025 | 02/14/2025 |
| Knobil Katharine | BUY | +30,000 | $1.59 | 02/12/2025 | 02/14/2025 |
| ELMS STEVE | BUY | +30,000 | $1.59 | 02/12/2025 | 02/14/2025 |
| ELMS STEVE | BUY | +11,085 | $3.20 | 12/23/2024 | 12/26/2024 |
| New Enterprise Associates 16, L.P. | BUY | +554,250 | $3.20 | 12/23/2024 | 12/23/2024 |
| Lurier Eliot M | OTHER | 0 | Not reported | 06/30/2023 | 07/05/2023 |
| ELMS STEVE | BUY | +8,000 | $1.72 | 06/06/2023 | 06/08/2023 |
| Wilson John Robert | BUY | +8,000 | $1.72 | 06/06/2023 | 06/08/2023 |
| Knobil Katharine | BUY | +8,000 | $1.72 | 06/06/2023 | 06/08/2023 |
| Eansor Norman David | BUY | +8,000 | $1.72 | 06/06/2023 | 06/08/2023 |
| Eansor Norman David | SELL | -14,285 | Not reported | 03/25/2021 | 06/08/2023 |
| Eansor Norman David | BUY | +14,285 | $17.50 | 03/16/2021 | 06/08/2023 |
| Vera Juan | BUY | +100,000 | $1.42 | 05/10/2023 | 05/11/2023 |